6/20/2025  5:31:27 PM Chg. -0.70 Volume Bid6:40:00 PM Ask6:40:00 PM Market Capitalization Dividend Y. P/E Ratio
259.30CHF -0.27% 5.05 mill.
Turnover: 1.31 bill.
-Bid Size: 50 258.00Ask Size: 1 235.65 bill.CHF 3.74% 24.96

Business description

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
 

Management board & Supervisory board

CEO
Dr. Thomas Schinecker
Management board
Dr. Alan Hippe, Teresa Graham, Matt Sause , Cristina A. Wilbur, Claudia Böckstiegel, Prof. Dr. Hans Clevers, Dr. Levi Garraway, Silke Hörnstein, Wafaa Mamilli, Dr. Aviv Regev, Barbara Schädler, Boris L. Zaïtra
Supervisory board
Dr. Severin Schwan, André Hoffmann, Dr. Jörg Duschmalé, Dr. Patrick Frost, Anita Hauser, Prof. Dr. Akiko Iwasaki, Prof. Dr. Richard Lifton, Dr. Jemilah Mahmood, Dr. Mark Schneider, Dr. Claudia Süssmuth Dyckerhoff
 

Company data

Name: Roche Holding
Address: Grenzacherstraße 124,CH-4070 Basel
Phone: +41-61-688-1111
Fax: -
E-mail: basel.webmaster@roche.com
Internet: www.roche.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 87.84%
IPO date: 4/3/1995

Investor relations

Name: Bruno Eschli
IR phone: +41 (61) 687 5284
IR Fax: +41 (61) 691 0014
IR e-mail: bruno.eschli@roche.com

Company calendar

CW 30 | 7/24/2025 Interim Report 2nd Quarter/6 Months
CW 43 | 10/23/2025 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Group with pooled rights
 
64.97%
Others
 
27.45%
Maja Oeri
 
7.58%